Payment overview · 2025
General Payments
$378.64
22 reported records · 9 companies
Healthcare provider profile · identity verified
Deborah Gail Epling, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WILLIAMSON, WV · NPI 1255705760
Verified facts
What the public records show
CMS Open Payments records show Deborah Gail Epling, FNP-C received $378.64 in general payments during 2025 across 22 reported records.
ABBVIE INC. accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.93 | 50.4% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.70 | 12.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.95 | 9.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.08 | 5.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.84 | 5.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.52 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.66 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.38 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.58 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $378.64 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $148.58 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.74 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.98 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 628 | 87 |
| Lisinopril | Lisinopril | 380 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 295 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 50 |
| Clonazepam | Clonazepam | 233 | 38 |
| Omeprazole | Omeprazole | 223 | 40 |
| Montelukast Sodium | Montelukast Sodium | 211 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 36 |
| Metformin Hcl | Metformin Hcl | 150 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 42 |
| Simvastatin | Simvastatin | 135 | 23 |
| Furosemide | Furosemide | 134 | 31 |
| Ibuprofen | Ibuprofen | 131 | 37 |
| Famotidine | Famotidine | 130 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 124 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 51 |
| Trazodone Hcl | Trazodone Hcl | 122 | 20 |
| Prednisone | Prednisone | 119 | 62 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 17 |
| Atenolol | Atenolol | 97 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 17 |
| Buspirone Hcl | Buspirone Hcl | 93 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 19 |
| Tramadol Hcl | Tramadol Hcl | 92 | 27 |
| Methocarbamol | Methocarbamol | 90 | 19 |
| Ozempic | Semaglutide | 89 | 20 |
| Diazepam | Diazepam | 87 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 22 |
| Alprazolam | Alprazolam | 79 | suppressed |
| Fluconazole | Fluconazole | 79 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 15 |
| Glipizide | Glipizide | 77 | 19 |
| Potassium Chloride | Potassium Chloride | 76 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 16 |
| Azithromycin | Azithromycin | 66 | 57 |
| Carvedilol | Carvedilol | 66 | 14 |
| Mirtazapine | Mirtazapine | 65 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Amoxicillin | Amoxicillin | 57 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 14 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Losartan Potassium | Losartan Potassium | 54 | 12 |
| Meloxicam | Meloxicam | 52 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 23 |
| Clonidine Hcl | Clonidine Hcl | 50 | 11 |
| Ezetimibe | Ezetimibe | 49 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 11 |
| Promethazine Hcl | Promethazine Hcl | 46 | 12 |
| Sertraline Hcl | Sertraline Hcl | 45 | 14 |
| Ondansetron Odt | Ondansetron | 43 | 17 |
| Cilostazol | Cilostazol | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 26 |
| Eliquis | Apixaban | 38 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Clonidine | Clonidine | 36 | suppressed |
| Lidocaine | Lidocaine | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 28 | 27 |
| Ofloxacin | Ofloxacin | 28 | 25 |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Jardiance | Empagliflozin | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Buprenorphine | Buprenorphine | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $378.64 · 22 records | ABBVIE INC. | Auvelity, BREZTRI, CAPLYTA, Fluad, Flucelvax, Ozempic, PAXLOVID, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error